The Use of Tissue Plasminogen Activator to Declot Arteriovenous Accesses in Hemodialysis Patients
- 1 January 1993
- journal article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 21 (1) , 38-43
- https://doi.org/10.1016/s0272-6386(12)80718-9
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- A Patient with Recurrent Thrombosis in Polytetrafluoroethylene Dialysis GraftsSeminars in Dialysis, 1990
- Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group.Circulation, 1989
- Thrombolytic therapy: A review (Part 1 of 2)Cleveland Clinic Journal of Medicine, 1989
- RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISMThe Lancet, 1988
- Transluminal angioplasty of venous stenoses in polytetrafluoroethylene vascular access graftsKidney International, 1987
- The Role of Thrombolysis in Hemodialysis Access OcclusionAmerican Journal of Kidney Diseases, 1987
- Arterial and venous embolization: declotting of dialysis shunts by direct injection of streptokinase.Radiology, 1986
- Vascular Access for Hemodialysis Patency Rates and Results of RevisionAnnals of Surgery, 1985
- Thrombosed synthetic hemodialysis access fistulas: failure of fibrinolytic therapy.Radiology, 1985
- Urokinase Treatment for Arteriovenous Fistulae Declotting in Dialyzed PatientsNephron, 1984